Global Markets Direct’s, ‘Lupus Nephritis – Pipeline Review, H2 2015′, provides an overview of the Lupus Nephritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lupus Nephritis Overview 9
Therapeutics Development 10
Pipeline Products for Lupus Nephritis - Overview 10
Pipeline Products for Lupus Nephritis - Comparative Analysis 11
Lupus Nephritis - Therapeutics under Development by Companies 12
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 15
Lupus Nephritis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Lupus Nephritis - Products under Development by Companies 19
Lupus Nephritis - Products under Investigation by Universities/Institutes 21
Lupus Nephritis - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Asahi Kasei Pharma Corp. 23
Azano Pharmaceuticals Inc. 24
Biogen, Inc. 25
Bristol-Myers Squibb Company 26
Deltanoid Pharmaceuticals Inc. 27
F. Hoffmann-La Roche Ltd. 28
FibroStatin SL 29
GlaxoSmithKline Plc 30
HanAll Biopharma Co., Ltd. 31
Invion Limited 32
Millennium Pharmaceuticals, Inc. 33
Ocata Therapeutics, Inc. 34
Zyrnat Biotherapeutics SL 35
Lupus Nephritis - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
abatacept - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
belimumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BIIB-023 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BMS-986147 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DP-001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
FSMAB-26 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-161 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
INV-103 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ixazomib citrate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
mizoribine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Monoclonal Antibody for Lupus Nephritis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
obinutuzumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
P-Dex - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RO-5461111 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
venetoclax - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
voclosporin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Y-175L - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ZY-11 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Lupus Nephritis - Recent Pipeline Updates 81
Lupus Nephritis - Dormant Projects 103
Lupus Nephritis - Discontinued Products 105
Lupus Nephritis - Product Development Milestones 106
Featured News & Press Releases 106
Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis 106
Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 106
Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 107
Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 107
May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH 108
Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease 109
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables

Number of Products under Development for Lupus Nephritis, H2 2015 10
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Development by Companies, H2 2015 (Contd...1) 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd...1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Lupus Nephritis - Pipeline by AbbVie Inc., H2 2015 22
Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2015 23
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2015 24
Lupus Nephritis - Pipeline by Biogen, Inc., H2 2015 25
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2015 26
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015 27
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 28
Lupus Nephritis - Pipeline by FibroStatin SL, H2 2015 29
Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2015 30
Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 31
Lupus Nephritis - Pipeline by Invion Limited, H2 2015 32
Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 33
Lupus Nephritis - Pipeline by Ocata Therapeutics, Inc., H2 2015 34
Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Stage and Target, H2 2015 38
Number of Products by Stage and Mechanism of Action, H2 2015 40
Number of Products by Stage and Route of Administration, H2 2015 42
Number of Products by Stage and Molecule Type, H2 2015 44
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H2 2015 81
Lupus Nephritis - Dormant Projects, H2 2015 103
Lupus Nephritis - Dormant Projects (Contd...1), H2 2015 104
Lupus Nephritis - Discontinued Products, H2 2015 105

List of Figures

Number of Products under Development for Lupus Nephritis, H2 2015 10
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Top 10 Targets, H2 2015 37
Number of Products by Stage and Top 10 Targets, H2 2015 37
Number of Products by Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Top 10 Routes of Administration, H2 2015 41
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 41
Number of Products by Top 10 Molecule Types, H2 2015 43
Number of Products by Stage and Top 10 Molecule Types, H2 2015 43